An evidence-anchored ranking of senolytics — Dasatinib+Quercetin, fisetin, navitoclax, FOXO4-DRI — showing what human and mouse data actually support, and where the field has failed.
BAM15 is a mitochondrial uncoupler studied in cell and rodent metabolic research. What it is, how it works, the evidence, and why it is compared to DNP.
Cagrilintide (AM833) is a long-acting amylin analogue and dual amylin/calcitonin receptor agonist. Its chemistry, receptor pharmacology, and trial evidence, RUO.
Humanin is a 24-amino-acid mitochondrial-derived peptide encoded in the 16S rRNA region, studied in ageing, apoptosis and metabolic biology. RUO overview.
Adipotide (FTPP / Prohibitin-TP01) is a chimeric peptidomimetic studied for targeting white-fat blood vessels. What the primate and mouse data actually show — RUO.
FOXO4-DRI is a D-retro-inverso senolytic peptide that disrupted the FOXO4-p53 interaction and cleared senescent cells in aged mice. What the research actually shows.
SLU-PP-915 is a synthetic, orally bioavailable pan-ERR agonist. What the mouse and in-vitro literature actually shows, and where the evidence is still thin.
A naturally occurring polyamine that induces autophagy from yeast to mice, backed by striking mortality epidemiology — and undercut by randomised human trials that keep underdelivering. An honest scorecard.
A small molecule made untrained mice run dramatically further. Two decades and several large human trials later, acadesine’s record is a study in how rodent spectacle and clinical reality diverge.
Elamipretide is the most clinically advanced cardiolipin-targeting tetrapeptide ever tested — now an approved Barth-syndrome drug, yet with a trial record that is the field’s sharpest cautionary tale.
Cookies
We use strictly necessary cookies to run the store. With your consent we also use analytics (order attribution) and marketing (Omnisend) cookies. Read our Cookie Policy.
